Eosinophilic esophagitis (EoE) is a chronic, food-driven allergic disease resulting in eosinophilic 30 esophageal inflammation. We recently found that EoE susceptibility is associated with genetic 31 variants in the promoter of CAPN14, a gene with reported esophagus-specific expression. CAPN14 32 is dynamically up-regulated as a function of EoE disease activity and after exposure of epithelial 33 cells to interleukin-13 (IL-13). Herein, we aimed to explore molecular modulation of CAPN14 34 expression. We identified three putative binding sites for the IL-13-activated transcription factor 35 STAT6 in the promoter and first intron of CAPN14. Luciferase reporter assays revealed that the two 36 most distal STAT6 elements were required for the ~10-fold increase in promoter activity subsequent 37
48

INTRODUCTION 49
Eosinophilic esophagitis (EoE) is a chronic, allergic disease associated with marked mucosal 50 eosinophil accumulation (Liacouras et al. 2011 ). EoE remits after removal of specific food types, and 51 food re-introduction causes disease reoccurrence, including dysregulation of esophageal transcripts. 52
The etiology of EoE includes environmental, immunological, and genetic components (Alexander et variants among these phenotypes suggests that these loci contain variants that participate in the 63 allele-dependent regulation of a molecular pathway that is central to the etiology of allergic disease. 64 65 We recently found that, in addition to genetic risk loci for allergic sensitization, EoE susceptibility is 66 linked to one or more genetic factors at 2p23, encoding the CAPN14 gene ). This 67 genetic linkage has been replicated at genome-wide significance in multiple cohorts, as well as in a 68 recent independent study (Sleiman et al. 2014) , adding credence to the importance of the 2p23 69 genetic linkage. CAPN14 (encoding calpain-14) belongs to the classical calpain sub-family, a set of 70 calcium activated intracellular regulatory proteases (Sorimachi et al. 2011) . In our initial studies, we 71 identified CAPN14 as dynamically up-regulated as a function of EoE disease activity as well as after 72 exposure of epithelial cells to IL-13 (Davis et al. 2016) . Expression quantitative trait loci (eQTL) 73 analysis revealed that patients with active EoE expressed CAPN14 in a genotype-dependent 74 manner . While CAPN14 was expressed at a higher level in individuals with EoE 75 compared to those without EoE, patients with the risk genotype had decreased expression of 76 CAPN14 compared to patients with the non-risk genotype . Consistent with these findings, 77 overexpression of the calpain-14 protein in esophageal epithelial cells leads to morphological 78 changes and barrier defects independently of IL-13-mediated inflammation, while CAPN14 gene 79 silencing in these cells leads to defects in barrier repair after IL-13 stimulation (Davis et al. 2016) , 80
suggesting that calpain-14 might contribute to EoE via a regulatory loop (Litosh et al. 2017) . 81
82
In this study, we aimed to identify regulatory factors that control the expression of CAPN14. Using 83 luciferase reporter constructs, we determined that IL-13 is sufficient to induce CAPN14 promoter 84 activity and identified one putative STAT6 binding sites as necessary for IL-13-induced CAPN14 85 promoter activity with a second putative STAT6 binding site in the promoter necessary for full 86 induction of CAPN14 promoter activity. Using chromatin immunoprecipitation, we identified STAT6 87 binding to the promoter of CAPN14 at the site of the two putative STAT6 binding sites in EPC2 88 esophageal epithelial cells. One single nucleotide polymorphism (SNP) that is highly associated with 89 EoE risk and located in the promoter of CAPN14 was sufficient to decrease CAPN14 promoter 90 activity in a manner that is consistent with the eQTL seen in individuals with and without EoE (Kottyan 91 et al. 2014 ). By measuring mRNA and protein expression of CAPN14/calpain-14 over a variety of in 92 vitro culture conditions, we further found that CAPN14 expression is highest in differentiated 93 esophageal epithelial cells after IL-13 exposure. IL-4 also signals in esophageal epithelial cells in a 94 STAT6-dependent manner, and we obtained consistent results for IL-4 and IL-13 promoter activity 95 and gene expression. Altogether, this study identified immunological, genetic, and epithelial cell 96 differentiation mechanisms that regulate the expression of CAPN14. 97
98
METHODS 99
Esophageal epithelial cell cultures. EPC2 esophageal epithelial cells were grown in keratinocyte 100 serum-free media (K-SFM) (Life Technologies, Grand Island, NY) to various levels of confluence 101 (80% or 100%) with relatively low (0.09 mM) or high (1.8 mM) Ca 2+ and with or without 100 ng/mL 102 IL-13 or IL-4 for 24 hours, as a monolayer submerged culture or in an air-liquid interface (ALI) culture 103 (Davis et al. 2016; Kottyan et al. 2014 ). For the ALI culture system, the esophageal epithelial EPC2 104 cell line was grown to confluence on 0.4 μm pore-size polyester permeable supports (Corning 105 Incorporated, Corning, NY) in K-SFM supplemented with 1.8 mM calcium. Epithelial differentiation 106 was then induced by removing culture media from the inner chamber of the permeable support and 107 maintaining the esophageal epithelial cells for 8 days in the ALI in the presence or absence of IL-13 108 or IL-4 (100 ng/mL). TE7 esophageal epithelial cells were grown in RPMI1640 supplemented with 109 10% FBS (HyClone, Pittsburgh, PA). 110
Luciferase reporter assays. The CCL26 nanoluciferase reporter construct was engineered using 111 the firefly reporter construct reported previously (Lim et al. 2011 ). The first 964 bp before the CCL26 112 start codon were subcloned into the pNL1.1 nanoluciferase reporter vector (Promega, Madison, WI). 113
For the CAPN14 promoter reporter construct, PCR primers (listed in Table S1) were used to amplify 114 the 1988 base pair region around rs76562819 and subsequently clone it into the pNL1.1 115 nanoluciferase reporter vector. Site-directed mutagenesis was performed to generate the construct 116 with scrambled STAT6 binding sites and the EoE non-risk allele of rs76562819 using the GeneArt 117
Site-Directed Mutagenesis System (Invitrogen, Darmstadt, Germany). Sequences were confirmed 118 by Sanger sequencing. All mutagenesis primers are provided in Table S1 . 119 250 ng of nanoluciferase experimental constructs were transiently co-transfected into esophageal 120 epithelial cells with 250 ng of pGL3-control firefly luciferase reporter plasmid. After 24 hours, cells were treated with 100 ng/mL of IL-13 or IL-4 (Promega, Madison, WI). 24 hours after cytokine 122 administration, cells were lysed and nano and firefly luciferase activity was assayed using the 123 Promega Nano-Glo Luciferase Assay System. The nanoluciferase measurement for each well was 124 divided by the firefly luciferase measurement in order to account for cytotoxicity, small differences in 125 cell number, and transfection efficiency. Each well was further normalized to the promoterless 126 pNL1.1 vector to control for baseline activity of the vector. 127
Chromatin immunoprecipitation analysis. EPC2 cells were treated with IL-13 at 100 ng/mL for 45 128 min and fixed with 1% formaldehyde for ChIP. ChIP was performed as reported previously (Rochman 129 et al. 2015) with the exception that the sonication was for 4 min and ChIP was performed manually 130 for the anti-STAT6 experiments. Anti-STAT6 antibody S-20 (D3H4 Rabbit mAb #5397, Cell 131
Signaling) anti-H3K4me3 antibody ab8580 (Abcam), and anti-H3K27Ac antibody ab4279 (Abcam). 132
We fixed 10-20×10 6 cells with 0.8% formaldehyde by adding 1 ml of 10X fixation buffer (50 mM 133
Hepes-KOH, pH 7.5; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 8% formaldehyde) to 9 ml of growth 134 medium for 8 minutes at room temperature with shaking. The reaction was stopped by adding glycine 135 to a final concentration of 125 mM for an additional 5 minutes. After washing with PBS, pellets were 136 frozen at −80°C for at least overnight. Nuclei were prepared by re-suspending pellets in 1 ml of L1 137 buffer (50 mM Hepes-KOH, pH 7.5; 140 mM NaCl; 1 mM EDTA; 10% glycerol; 0.5% NP-40; 0.25% 138 Triton X-100) and incubated at 4°C for 10 min. Nuclei were pelleted and re-suspended in 1 ml of L2 Gene Expression Assays CAPN14-Hs00871882_m1, CCL26-Hs00171146_m1 and GAPDH-157
Hs02786624_g1. Relative quantification was calculated by the comparative CT method (Livak and 158
Schmittgen 2001). Briefly, expression levels for CAPN14 or CCL26 were normalized to levels of 159 GAPDH. All samples were then normalized to cells grown at 80% confluence without high calcium 160
or IL-13 and the data were exponentially transformed. 161
For the RNA-sequencing study performed to identify the isoforms of CAPN14 expressed in the Table S1 ) were used to amplify the 1988 base pair region 185 around rs76562819 and subsequently clone it into the pNL1.1 nanoluciferase reporter vector. All 186 mutagenesis primers are provided in Table S1 . RNA sequencing data has been deposited in NCBI 187
Geo database as GSE113341. 188
RESULTS
189
IL-13 administration to esophageal epithelial cells is sufficient to induce CAPN14 expression similar 190 to CCL26, a chemokine whose promoter activity is dependent on the STAT6 transcription factor (Lim 191 et al. 2011 ). Based upon these previous results, we hypothesized that IL-13 acted through the 192 transcription factor STAT6 to directly promote CAPN14 expression. Thus, we first constructed 193 promoter reporters by placing the promoters of either CAPN14 or CCL26 in front of the 194 nanoluciferase gene (Figure 1 A) . After treatment with IL-13 or IL-4, esophageal epithelial cells 195 transfected with the CAPN14 reporter construct exhibited a similar upregulation of nanoluciferase 196 expression to the cells transfected with a CCL26 reporter construct (Figure 1 B and Figure S1 A) . 197
Based upon the canonical 5'-TTC...GAA-3' core motif of STAT6, we identified two putative STAT6 198 binding sequences in the promoter located within 90 base pairs of the transcription start site of 199 CAPN14 and one putative STAT6 binding site in the first intron of CAPN14. We tested the necessity 200 of each individual predicted STAT6 binding site for IL-13-induced promoter activity by creating 201 luciferase reporter constructs with mutated putative STAT6 sites (Figure 1 A) . Mutation of the first 202 STAT6 site attenuated IL-13-mediated induction of CAPN14 promoter activity, while mutation of the 203 second STAT6 site completely blocked CAPN14 promoter induction (Figure 1 C) . Mutation of the 204 third putative STAT6 site in the first intron of CAPN14 did not affect the promoter activity of CAPN14 205
following treatment with IL-13 (Figure 1 C) . From these experiments, we concluded that the two 206 sites in the promoter are necessary for full IL-13-induced promoter activity. 207
208
Chromatin immunoprecipitation of STAT6 in esophageal epithelial cells treated with IL-13 was used 209 to further establish STAT6 binding to the promoter of CAPN14 at the two binding sites that were 210 necessary for IL-13-inducible CAPN14 promoter activity. We identified ChIP-seq peaks in the 211 promoter of CAPN14 spanning these two STAT6 sites from chromatin extracted from IL-13 212 stimulated esophageal epithelial cells (Figure 2) . There was no evidence of STAT6 binding at the 213 third putative STAT6 site in the first intron of CAPN14. These STAT6 ChIP-seq peaks overlap ChIP-214 seq peaks from active histone marks H3K4me3 and H3K27Ac that appear after induction by IL-13 215 (Figure 2) . Altogether, these functional genomic data support our initial hypothesis that IL-13 and 216 IL-4 activate CAPN14 expression through the binding of STAT6 to two sites in the promoter of 217
CAPN14. 218
Patients with EoE and the genetic-risk haplotype at 2p23, marked by single nucleotide polymorphism 220 (SNP) rs76562819, have 50% less CAPN14 in their esophageal biopsies compared to patients with 221 the non-risk haplotype ). An analysis of differential isoform usage of CAPN14 222 identified two major isoforms of CAPN14 that did not change with EoE disease status or sex, ( Figure  223   S2) . Of the two isoforms of CAPN14 that are expressed, the major isoform (ENST00000444918) 224 includes exon 7, while the less highly expressed isoform of CAPN14 (ENST00000398824) does not. . We tested the hypothesis that rs76562819 was sufficient to 230 result in genotype-dependent promoter activity of CAPN14 using two identical luciferase constructs 231 containing the promoter and a portion of the first intron of CAPN14 with either the risk or the non-232 risk allele of rs76562819 (Figure 3 A) . We found that the EoE risk allele at rs76562819 resulted in 233 a 40.0% reduction of IL-13 and IL-4-induced CAPN14 promoter activity compared to the EoE non-234 risk allele (Figure 3 B) . Thus, the single base change from non-risk to risk at rs76562819 is sufficient 235 to explain most of the reduced CAPN14 promoter activity in the luciferase reporter assays. These 236 results are consistent with the genotype at rs76562819 accounting for genotype-dependent 237 expression observed in EoE patient biopsies. 238
239
We next sought to determine the factors leading to expression of CAPN14 in esophageal epithelium. 240
Unlike CCL26, CAPN14 expression is highly dependent upon the cell culture conditions. Esophageal 241 epithelial differentiation is a physiological process that increases mechanical strength and barrier air-liquid interface (ALI), CAPN14 mRNA expression is low (Figure 4 A) . Following differentiation, 246 CAPN14 is induced 10,000-fold in the ALI, p<0.0001 (Figure 4 A) . At a protein level, calpain-14 was 247 detected only in the most differentiated system (ALI) following treatment with IL-13 (Figure 4 B) . As 248 seen in the promoter reporter experiments, IL-4 and IL-13 are equally capable of induction of 249 CAPN14 mRNA and protein (Figure S3) . 250
251
DISCUSSION 252
Altogether, we identified immunological (IL-13/IL-4/STAT6), genetic (rs76562819), and epithelial 253 differentiation factors that regulate the expression of CAPN14. These results are important because 254 calpain-14 represents a candidate for treatment and prevention of EoE. Previous studies supported 255 a model in which IL-13 induction of CAPN14 occurs in a STAT6-dependent manner. We identified 256 the STAT6 binding sites, the necessity of these sites for CAPN14 promoter activity, and the binding 257 of STAT6 to the promoter of CAPN14 in esophageal cells stimulated with IL-13. We demonstrated 258 genotype-dependent expression of CAPN14 and identified rs76562819 as the genetic variant that is 259 sufficient to produce genotype-dependent promoter activity. Indeed, the 40.0% reduction of CAPN14 260 promoter activity in the genotype-dependent reporter assays mirrors the effect size of the eQTLs 261 measured in subjects with and without EoE ). The reporter experiments did not 262 demonstrate statistically significant genotype-dependent promoter activity in cells that were not 263 stimulated with IL-13. This could be due to several factors, including the sensitivity of the reporter 264 system, the non-differentiated context of the reporter experiments, or the fact that IL-13 is needed 265 for genotype-dependent CAPN14 promoter activity. The fact that relatively undifferentiated 266 esophageal epithelial cell culture systems are sufficient for luciferase reporter systems could be due 267 to how differentiation affects chromatin availability -a factor that is not assessed in the cytoplasmic 268 luciferase reporter assay. CAPN14 mRNA and protein expression levels strongly support the 269 conclusion that both differentiation and stimulation with IL-13 or IL-4 is critical for the highest 270 expression of calpain-14 in esophageal epithelial cells. The requirement for esophageal epithelial 271 cell differentiation before CAPN14 expression might be the primary mechanism through which 272 CAPN14's expression is induced in the esophageal mucosa. in response to IL-13 can regulate the expression of other genes). It was therefore important to 285 establish that two STAT6 sites in the CAPN14 promoter control IL-13-stimulated expression of 286 CAPN14. IL-13 shares many functional properties with IL-4, stemming from the fact that they share 287 a common receptor subunit, the alpha subunit of the IL-4 receptor (Hershey 2003) . Both IL-13 and 288 IL-4 signaling lead to STAT6 dimerization, phosphorylation, and nuclear translocation (Kuperman 289 and Schleimer 2008), so it is therefore not surprising that IL-4 might also regulate CAPN14 mRNA 290 expression and promoter activity (Figures S1 and S3) . Despite the evidence presented in this study, 291 future experiments in esophageal epithelial cells deficient in STAT6 signaling are needed to fully 292 conclude that STAT6 is necessary in the transcription of CAPN14. by IL-13 are expressed in various epithelial context (e.g. CCL26/eotain-3), other genes have more 300 nuainced regulatory factors affecting expression (e.g. CAPN14/calpain-14). In this study, we 301 demonstrated that epithelial differentiation was important; however, we were unable to establish 302 specific tissue-specific molecular pathways that lead to the differences in CCL26 and CAPN14 303 expression in response to This study focused on the regulation of CAPN14 transcription. Future studies will assess the post- (Figure 4 B) . We used an overexpression 310 construct of calpain-14 to identify the specific band bound by the anti-calpain-14 antibody in the 311 Western blots (Figure 4 B) 
